Table 3 Summary of Cost ($) and Outcome Results in the base-case analysis
Strategy | Cost | Expected LYs | QALYs | ICERa | Comments |
|---|---|---|---|---|---|
United States | |||||
 Sunitinib | 297,693 | 3.01 | 2.04 | NA | Cost-effective |
 Nivolumab plus ipilimumab | 362,807 | 4.18 | 2.80 | 85,506 | |
United Kingdom | |||||
 Sunitinib | 75,034 | 3.01 | 2.02 | NA | Not cost-effective |
 Nivolumab plus ipilimumab | 169,390 | 4.18 | 2.77 | 126,499 | |
China | |||||
 Sunitinib | 97,846 | 3.01 | 1.96 | NA | Cost-effective |
 Nivolumab plus ipilimumab | 101,132 | 4.18 | 2.66 | 4682 | |